Analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Leap Therapeutics in a research report issued on Wednesday, January 29th. HC Wainwright analyst S. Ramakanth ...
Additional updates on the progression free survival data provide a future catalyst, with LPTX planning to provide updates in 2025. LPTX plans to run a phase 3 study of DKN-01 in colorectal cancer ...
Leap Therapeutics (NASDAQ:LPTX) fell ~12% on Wednesday as Baird downgraded the stock after the biotech said its lead candidate, sirexatamab, generated disappointing data in a mid-stage trial for ...
Leap Therapeutics (NASDAQ:LPTX – Get Free Report) was downgraded by investment analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a research note issued on Wednesday ...
Jan. 28, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced positive initial data ...
Data is not available at this time. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is ...
Leap Therapeutics stock plummets as it will discontinue DisTinGuish study in advanced gastric cancer
Investing.com -- Shares of Leap Therapeutics (NASDAQ:LPTX) tumbled 64% in pre-open trading Tuesday as the company announced that its DisTinGuish study of sirexatamab combined with tislelizumab and ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results